Omeros (NASDAQ:OMER) Stock, Quote.Headers.trade-ideas

Omeros

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

John Deere.Shutterstock

Earnings

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ASTS

BMTX

EYEN

OMER

SPIR

TSRI

Crude Oil Moves Higher; Deere Cuts Profit Outlook

Movers

ADTH

AWIN

BRSH

BSFC

COIN

CRBG

CRKN

DADA

EXTR

FFIE

FLNT

GAMB

GOOS

GWAV

KULR

LSDI

LSPD

MGNI

NICE

PEGY

REKR

RELI

SBOW

SDOT

SINT

TIRX

TRUP

WOOF

Why Fluent Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Stock Market

US Stocks Edge Higher; Initial Jobless Claims Fall

Omeros Corp

OMEROS ORD

Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) reported quarterly losses of $(0.97) per share which beat the analyst consensus estimate of $(1.14) by 14.91 percent.

Earnings Beats

Omeros Q2 2024 GAAP EPS $(0.97) Beats $(1.14) Estimate

Needham analyst Serge Belanger reiterates Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) with a Hold.

Reiteration

Analyst Ratings

Needham Reiterates Hold on Omeros

<ul>
<li>$118.1 million, or 55%, of outstanding convertible notes due in 2026 repurchased at approximately 75% of notional value, resulting in $51 million in total debt extinguishment</li>
<li>Repurchase funded from new $67 million secured four-year term loan maturing in June 2028 together with $21 million cash on hand</li>
<li>Credit facility includes $25 million delayed draw term loan conditionally available to fund narsoplimab commercialization</li>
<li>Transactions include no equity component, preventing shareholder dilution, and enable additional debt reduction</li>
</ul>

Omeros Entered Into Credit And Guaranty Agreement to Provide Senior Secured Term Loan Facility Initially Up To $92.1M

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite falling around 0.1% on Thursday.
The Dow traded up 0.01% to 39,912.06 while the NASDAQ fell 0.10% to 16,726.17. The S&amp;P 500 also fell, dropping, 0.04% to 5,306.04.
Check This Out: <a href="https://www.benzinga.com/news/24/05/38871724/oklo-is-too-risky-jim-cramer-says-buy-this-general-electric-spinoff-instead">Oklo Is &#8216;Too Risky,&#8217; Jim Cramer Says: Buy This General Electric Spinoff Instead</a>
Leading and Lagging Sectors Consumer staples shares rose by 1.7% on Thursday.
In trading on Thursday, materials shares fell by 0.5%.
Top Headline
Deere &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) reported upbeat second-quarter earnings, but lowered its net income 2024 outlook.
The company's net sales and revenue declined 12% year-over-year to $15.235 billion, beating the consensus of $13.281 billion. EPS of $8.53, down from $9.65 YoY, beating the consensus of $7.87.
Deere lowered its 2024 net income outlook to $7.00 billion (prior $7.50 billion-$7.75 billion).
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>BM Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMTX#NASDAQ">BMTX</a>) shares shot up 41% to $2.4026 after the company reported better-than-expected first-quarter financial results.</li>
<li>Shares of AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) got a boost, surging 57% to $3.7486 after the company and AT&amp;T announced a definitive commercial agreement. The company also reported mixed first-quarter financial results.</li>
<li>TSR, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSRI#NASDAQ">TSRI</a>) shares were also up, gaining 65% to $13.12 after the company announced that it entered into a definitive agreement to be acquired by Vienna Parent.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Eyenovia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) shares dropped 24% to $0.8101 after the company reported worse-than-expected first-quarter financial results.</li>
<li>Shares of Spire Global, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NYSE">SPIR</a>) were down 20% to $9.07 after the company reported mixed first-quarter financial results on Wednesday.</li>
<li>Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) was down, falling 20% to $3.35 after the company announced a wider-than-expected quarterly loss.</li>
</ul>
Also Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/05/38872349/over-1m-bet-on-this-healthcare-stock-check-out-these-3-stocks-insiders-are-buying">Over $1M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying</a>
Commodities In commodity news, oil traded up 0.7% to $79.18 while gold traded down 0.4% at $2,386.30.
Silver traded up 0.6% to $29.91 on Thursday, while copper fell 1% to $4.8750.
Euro zone
European shares were lower today. The eurozone's STOXX 600 slipped 0.21%, Germany's DAX fell 0.69% and France's CAC 40 fell 0.63%. Spain's IBEX 35 Index fell 0.56%, while London's FTSE 100 fell 0.08%.
Italy reported a trade surplus of EUR 4.341 billion in March, versus a year-ago surplus of EUR 3.327 billion. The annual inflation rate in Italy slowed to 0.8% in April versus 1.2% a month ago.
Asia Pacific Markets
Asian markets closed higher on Thursday, with Japan's Nikkei gaining 1.39%, China's Composite Index climbing 1.59%, Hong Kong's Hang Seng Index gaining 0.08% and India's S&amp;P BSE Sensex gaining 0.7%.
Industrial production in Japan rose by 4.4% month-over-month in March following a 0.6% decline in the earlier month. Japan's economy shrank by 2.0% in the first quarter, versus market expectations for a 1.5% decline.
Economics
<ul>
<li>U.S. initial jobless claims declined by 10,000 to 222,000 in the week ending May 11, compared to market estimates of 220,000.</li>
<li>U.S. housing starts increased 5.7% month-over-month to an annualized rate of 1.36 million in April, while building permits declined by 3% to 1.440 million.</li>
<li>U.S. industrial production came in little changed in April, compared to a 0.1% gain in March.</li>
<li>Import prices increased 0.9% month-over-month in April, while export prices rose 0.5% in April.</li>
<li>The Philadelphia Fed Manufacturing Index fell 11 points to a reading of 4.5 in May versus a reading of 15.5 in April.</li>
<li>U.S. natural-gas supplies rose 70 billion cubic feet during the week ended May 10.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/05/38872018/top-5-utilities-stocks-you-may-want-to-dump-in-may">Top 5 Utilities Stocks You May Want To Dump In May</a>

Shares of Fluent Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNT#NASDAQ">FLNT</a>) fell sharply during Thursday's session after posting weaker-than-expected <a href="https://www.benzinga.com/quote/FLNT/earnings">quarterly results.</a>
Fluent posted adjusted loss of 30 cents per share, versus market expectations for a loss of 10 cents per share. The company's quarterly sales came in at $65.983 million missing estimates of $66.433 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
Fluent shares dipped 12.6% to $3.47 on Thursday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Lucy Scientific Discovery Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSDI#NASDAQ">LSDI</a>) shares jumped 239% to $1.75.</li>
<li>Greenwave Technology Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWAV#NASDAQ">GWAV</a>) jumped 100% to $0.1196 after jumping around 34% on Wednesday.</li>
<li>Crown ElectroKinetics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRKN#NASDAQ">CRKN</a>) gained 77.3% to $0.0819 after declining around 3% on Wednesday.</li>
<li>BM Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMTX#NASDAQ">BMTX</a>) rose 68% to $2.8850 after the company reported better-than-expected first-quarter financial results.</li>
<li>TSR, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSRI#NASDAQ">TSRI</a>) shares climbed 65% to $13.13 after the company announced that it entered into a definitive agreement to be acquired by Vienna Parent.</li>
<li>Pineapple Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) rose 55% to $0.1355 after gaining around 48% on Wednesday. Pineapple Energy, last week, reported worse-than-expected first-quarter financial results.</li>
<li>Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) gained 48% to $0.1275 as the company shared several commercial and technological accomplishments from the first quarter of 2024.</li>
<li>Faraday Future Intelligent Electric Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIE#NASDAQ">FFIE</a>) gained 33.3% to $0.94.</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) shares rose 32.6% to $3.1711 as the company reported a narrower-than-expected loss for its first quarter and announced a definitive commercial agreement with AT&amp;T Inc.</li>
<li>Bruush Oral Care Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRSH#NASDAQ">BRSH</a>) gained 30.7% to $0.0949.</li>
<li>Sintx Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) shares rose 27% to $0.1622 after surging 132% on Wednesday.</li>
<li>Canada Goose Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOOS#NYSE">GOOS</a>) jumped 23% to $14.10 following better-than-expected fourth-quarter earnings.</li>
<li>Magnite, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNI#NASDAQ">MGNI</a>) rose 21.6% to $11.91. Needham analyst Laura Martin reiterated Magnite with a Buy and maintained a $15 price target.</li>
<li>Blue Star Foods Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSFC#NASDAQ">BSFC</a>) gained 17.6% to $0.0760 after adding more than 15% on Wednesday.</li>
<li>Lightspeed Commerce Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LSPD#NYSE">LSPD</a>) climbed 15.3% to $14.74 following upbeat quarterly sales.</li>
<li>Trupanion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) rose 14.7% to $32.53 after B of A Securities upgraded the stock from Neutral to Buy and raised its price target from $35 to $49.</li>
<li>SilverBow Resources, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBOW#NYSE">SBOW</a>) gained 14.7% to $37.17 after the company announced that it entered into a definitive agreement to be acquired by Crescent Energy.</li>
<li>VinFast Auto Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFS#NASDAQ">VFS</a>) rose 12.8% to $4.79. VinFast received 27,649 pre-orders for the VF 3 in Vietnam after 66 hours of accepting deposits.</li>
<li>Corebridge Financial, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRBG#NYSE">CRBG</a>) gained 12.7% to $34.00 after AIG reached a deal to sell shares of its stock in the company to Nippon Life Insurance.</li>
<li>Extreme Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXTR#NASDAQ">EXTR</a>) rose 10.8% to $12.02.</li>
<li>Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) gained 6.9% to $63.99 following better-than-expected quarterly earnings.</li>
<li>ZTO Express (Cayman) Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTO#NYSE">ZTO</a>) shares climbed 6% to $22.67 following upbeat quarterly results</li>
<li>Chubb Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>) gained 4.1% to $263.28 following an SEC filing showed Berkshire Hathaway purchased shares of the stock. The 13F filing revealed Berkshire Hathaway had purchased 25.92 million Chubb shares valued at over $6.717 billion.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Spire Global, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NYSE">SPIR</a>) dipped 23.7% to $8.65 after the company reported mixed first-quarter financial results on Wednesday.</li>
<li>a.k.a. Brands Holding Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AKA#NYSE">AKA</a>) shares declined 22.7% to $22.80.</li>
<li>Eyenovia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) fell 22% to $0.8291 after the company reported worse-than-expected first-quarter financial results.</li>
<li>Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) fell 21.1% to $3.29 after the company announced a wider-than-expected quarterly loss.</li>
<li>Reliance Global Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELI#NASDAQ">RELI</a>) declined 19.2% to $0.2994. &#8211; Reliance Global Group is expected to host a conference call Monday, May 20, to discuss financial results for the first quarter.</li>
<li>Tian Ruixiang Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIRX#NASDAQ">TIRX</a>) dipped 17.8% to $2.81.</li>
<li>Rekor Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REKR#NASDAQ">REKR</a>) declined 16.6% to $1.51 after the company reported worse-than-expected first-quarter financial results.</li>
<li>Sadot Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDOT#NASDAQ">SDOT</a>) fell 16.6% to $0.2855 following first-quarter financial results.</li>
<li>KULR Technology Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KULR#NYSE">KULR</a>) shares fell 14.8% to $0.3976 after the company announced worse-than-expected first-quarter financial results.</li>
<li>AERWINS Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWIN#NASDAQ">AWIN</a>) shares fell 14% to $5.40 after jumping 132% on Wednesday.</li>
<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) shares fell 13.8% to $34.06 after dipping around 19% on Wednesday.</li>
<li>NICE Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NICE#NASDAQ">NICE</a>) declined 11.8% to $201.01 after the company reported first-quarter financial results. The company issued second-quarter adjusted revenue guidance with its midpoint below estimates.</li>
<li>Gambling.com Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAMB#NASDAQ">GAMB</a>) fell 9.8% to $7.64 after the company issued first-quarter financial results. Also, the company cut its FY24 revenue guidance below estimates.</li>
<li>AMC Entertainment Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) shares declined 9% to $4.9904 after tumbling 20% on Wednesday.</li>
<li>Petco Health and Wellness Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WOOF#NASDAQ">WOOF</a>) dipped 8.4% to $2.39. The company recently appointed Glenn Murphy as Executive Chairman of the Board of Directors, effective immediately.</li>
<li>AdTheorent Holding Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTH#NASDAQ">ADTH</a>) declined 7.4% to $3.1750. AdTheorent reported withdrawal of acquisition proposal from third party.</li>
<li>Dada Nexus Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DADA#NASDAQ">DADA</a>) shares fell 7% to $1.8688 following weak quarterly results.</li>
<li>Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) fell 4.3% to $210.53.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/05/38872018/top-5-utilities-stocks-you-may-want-to-dump-in-may">Top 5 Utilities Stocks You May Want To Dump In May</a>

Why Fluent Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>Lucy Scientific Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSDI#NASDAQ">LSDI</a>) shares moved upwards by 205.8% to $1.56 during Thursday's regular session. The company's market cap stands at $2.7 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) shares moved upwards by 31.66% to $0.17. The company's market cap stands at $20.6 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>Nanoviricides (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NNVC#AMEX">NNVC</a>) stock increased by 23.56% to $2.22. The market value of their outstanding shares is at $26.1 million. The company's, Q3 earnings came out yesterday. </li>
<li>Scorpius Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SCPX#AMEX">SCPX</a>) shares moved upwards by 23.35% to $0.1. The company's market cap stands at $3.4 million. </li>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) stock moved upwards by 23.29% to $0.14. The market value of their outstanding shares is at $3.0 million. </li>
<li>NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) stock increased by 19.98% to $3.88. The market value of their outstanding shares is at $40.9 million. As per the news, the Q1 earnings report came out 2 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock decreased by 24.1% to $0.81 during Thursday's regular session. The market value of their outstanding shares is at $41.0 million. The company's, Q1 earnings came out yesterday. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) stock decreased by 22.17% to $1.51. The company's market cap stands at $1.3 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) stock decreased by 20.99% to $3.29. The market value of their outstanding shares is at $190.9 million. The company's, Q1 earnings came out yesterday. </li>
<li>Elicio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELTX#NASDAQ">ELTX</a>) shares fell 17.31% to $8.6. The market value of their outstanding shares is at $87.9 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Biotricity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCY#NASDAQ">BTCY</a>) stock decreased by 11.41% to $1.01. The company's market cap stands at $9.5 million. </li>
<li>T2 Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>) stock decreased by 10.22% to $5.36. The market value of their outstanding shares is at $72.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATNF

BTCY

ELTX

NNVC

NRXP

ONCO

SCPX

TTOO

12 Health Care Stocks Moving In Thursday's Intraday Session

WIIM

Omeros shares are trading lower after the company reported worse-than-expected Q1 adjusted EPS results.

U.S. stocks traded slightly higher this morning on Thursday.
Following the market opening Thursday, the Dow traded up 0.01% to 39,913.23 while the NASDAQ rose 0.06% to 16,753.07. The S&amp;P 500 also rose, gaining, 0.06% to 5,311.26.
Check This Out: <a href="https://www.benzinga.com/news/24/05/38871724/oklo-is-too-risky-jim-cramer-says-buy-this-general-electric-spinoff-instead">Oklo Is &#8216;Too Risky,&#8217; Jim Cramer Says: Buy This General Electric Spinoff Instead</a>
Leading and Lagging Sectors Consumer staples shares rose by 1.1% on Thursday.
In trading on Thursday, materials shares fell by 0.4%.
Top Headline
U.S. initial jobless claims declined by 10,000 to 222,000 in the week ending May 11, compared to market estimates of 220,000.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Lucy Scientific Discovery Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSDI#NASDAQ">LSDI</a>) shares shot up 224% to $1.6750.</li>
<li>Shares of Greenwave Technology Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWAV#NASDAQ">GWAV</a>) got a boost, surging 77% to $0.1063 after jumping around 34% on Wednesday.</li>
<li>TSR, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSRI#NASDAQ">TSRI</a>) shares were also up, gaining 65% to $13.14 after the company announced that it entered into a definitive agreement to be acquired by Vienna Parent.</li>
</ul>
Equities Trading DOWN
<ul>
<li>KULR Technology Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KULR#NYSE">KULR</a>) shares dropped 26% to $0.3451 after the company announced worse-than-expected first-quarter financial results.</li>
<li>Shares of Spire Global, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NYSE">SPIR</a>) were down 24% to $8.63 after the company reported mixed first-quarter financial results on Wednesday.</li>
<li>Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) was down, falling 22% to $3.2398 after the company announced a wider-than-expected quarterly loss.</li>
</ul>
Also Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/05/38872349/over-1m-bet-on-this-healthcare-stock-check-out-these-3-stocks-insiders-are-buying">Over $1M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying</a>
Commodities In commodity news, oil traded up 1.3% to $79.68 while gold traded down 0.7% at $2,377.70.
Silver traded down 0.4% to $29.605 on Thursday, while copper fell 1.3% to $4.8595.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 slipped 0.06%, Germany's DAX fell 0.5% and France's CAC 40 fell 0.4%. Spain's IBEX 35 Index fell 0.18%, while London's FTSE 100 rose 0.1%.
Italy reported a trade surplus of EUR 4.341 billion in March, versus a year-ago surplus of EUR 3.327 billion. The annual inflation rate in Italy slowed to 0.8% in April versus 1.2% a month ago.
Asia Pacific Markets
Asian markets closed higher on Thursday, with Japan's Nikkei gaining 1.39%, China's Composite Index climbing 1.59%, Hong Kong's Hang Seng Index gaining 0.08% and India's S&amp;P BSE Sensex gaining 0.7%.
Industrial production in Japan rose by 4.4% month-over-month in March following a 0.6% decline in the earlier month. Japan's economy shrank by 2.0% in the first quarter, versus market expectations for a 1.5% decline.
Economics
<ul>
<li>U.S. initial jobless claims declined by 10,000 to 222,000 in the week ending May 11, compared to market estimates of 220,000.</li>
<li>U.S. housing starts increased 5.7% month-over-month to an annualized rate of 1.36 million in April, while building permits declined by 3% to 1.440 million.</li>
<li>U.S. industrial production came in little changed in April, compared to a 0.1% gain in March.</li>
<li>Import prices increased 0.9% month-over-month in April, while export prices rose 0.5% in April.</li>
<li>The Philadelphia Fed Manufacturing Index fell 11 points to a reading of 4.5 in May versus a reading of 15.5 in April.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/05/38872018/top-5-utilities-stocks-you-may-want-to-dump-in-may">Top 5 Utilities Stocks You May Want To Dump In May</a>

Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.58) by 8.62 percent.

Earnings Misses

Omeros Q1 2024 Adj EPS $(0.63) Misses $(0.58) Estimate

Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.55) by 14.55 percent. This is a 13.7 percent increase over losses of $(0.73) per share from the same period last year.

CORRECTION: Omeros Q4 EPS $(0.63) Misses $(0.55) Estimate

<h3>Companies Reporting Before The Bell</h3>
&bull; Mach Natural Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNR#NYSE">MNR</a>) is projected to report quarterly earnings at $0.92 per share on revenue of $213.43 million.
&bull; Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) is expected to report earnings for its fourth quarter.
&bull; Sachem Cap (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SACH#AMEX">SACH</a>) is projected to report quarterly earnings at $0.11 per share on revenue of $16.58 million.
&bull; Enservco (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ENSV#AMEX">ENSV</a>) is projected to report quarterly loss at $0.05 per share on revenue of $6.60 million.
&bull; NexGel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXGL#NASDAQ">NXGL</a>) is likely to report quarterly loss at $0.11 per share on revenue of $1.38 million.
&bull; Milestone Scientific (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MLSS#AMEX">MLSS</a>) is likely to report earnings for its fourth quarter.
&bull; SPAR Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGRP#NASDAQ">SGRP</a>) is estimated to report earnings for its fourth quarter.
&bull; Escalade (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESCA#NASDAQ">ESCA</a>) is estimated to report earnings for its fourth quarter.
&bull; LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) is likely to report quarterly loss at $1.73 per share on revenue of $2.28 million.
&bull; Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) is projected to report earnings for its fourth quarter.
&bull; Crown ElectroKinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRKN#NASDAQ">CRKN</a>) is expected to report earnings for its fourth quarter.
&bull; LM Funding America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMFA#NASDAQ">LMFA</a>) is estimated to report earnings for its fourth quarter.
&bull; DecisionPoint Sys (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/DPSI#AMEX">DPSI</a>) is expected to report earnings for its fourth quarter.
&bull; Edible Garden AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDBL#NASDAQ">EDBL</a>) is estimated to report earnings for its fourth quarter.
&bull; Laser Photonics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LASE#NASDAQ">LASE</a>) is expected to report earnings for its fourth quarter.
&bull; Terran Orbital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLAP#NYSE">LLAP</a>) is estimated to report quarterly loss at $0.20 per share on revenue of $32.81 million.
&bull; Sigma Lithium (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGML#NASDAQ">SGML</a>) is expected to report quarterly earnings at $0.18 per share on revenue of $105.82 million.
&bull; Vislink Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VISL#NASDAQ">VISL</a>) is estimated to report earnings for its fourth quarter.
&bull; Nano X Imaging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNOX#NASDAQ">NNOX</a>) is projected to report quarterly loss at $0.30 per share on revenue of $2.82 million.
&bull; Ondas Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONDS#NASDAQ">ONDS</a>) is estimated to report quarterly loss at $0.14 per share on revenue of $4.27 million.
&bull; TriSalus Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSI#NASDAQ">TLSI</a>) is projected to report quarterly loss at $0.69 per share on revenue of $5.45 million.
&bull; Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) is projected to report quarterly loss at $1.18 per share on revenue of $22.45 million.
<h3>Companies Reporting After The Bell</h3>
&bull; BurgerFi International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFI#NASDAQ">BFI</a>) is expected to report quarterly loss at $0.19 per share on revenue of $40.00 million.
&bull; AST SpaceMobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) is expected to report earnings for its fourth quarter.
&bull; PVH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) is expected to report quarterly earnings at $3.53 per share on revenue of $2.42 billion.
&bull; VirTra (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTSI#NASDAQ">VTSI</a>) is projected to report quarterly earnings at $0.15 per share on revenue of $9.37 million.
&bull; Motorsport Games (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSGM#NASDAQ">MSGM</a>) is estimated to report earnings for its fourth quarter.
&bull; Yield10 Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YTEN#NASDAQ">YTEN</a>) is estimated to report quarterly loss at $0.30 per share on revenue of $30 thousand.
&bull; OMNIQ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMQS#NASDAQ">OMQS</a>) is likely to report quarterly loss at $0.26 per share on revenue of $16.35 million.
&bull; FlexShopper (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FPAY#NASDAQ">FPAY</a>) is projected to report quarterly loss at $0.25 per share on revenue of $30.51 million.
&bull; Stryve Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNAX#NASDAQ">SNAX</a>) is estimated to report quarterly loss at $1.96 per share on revenue of $5.01 million.
&bull; Air Industries (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIRI#AMEX">AIRI</a>) is expected to report quarterly loss at $0.34 per share on revenue of $12.40 million.
&bull; Eastside Distilling (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EAST#NASDAQ">EAST</a>) is expected to report quarterly loss at $0.90 per share on revenue of $3.68 million.
&bull; BIO-key Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKYI#NASDAQ">BKYI</a>) is expected to report earnings for its fourth quarter.
&bull; SKYX Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYX#NASDAQ">SKYX</a>) is likely to report quarterly loss at $0.08 per share on revenue of $21.12 million.
&bull; Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) is projected to report earnings for its fourth quarter.
&bull; Natural Gas Services Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGS#NYSE">NGS</a>) is estimated to report quarterly earnings at $0.06 per share on revenue of $30.30 million.
&bull; TOMI Environmental Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOMZ#NASDAQ">TOMZ</a>) is expected to report quarterly loss at $0.01 per share on revenue of $2.86 million.
&bull; Canoo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOEV#NASDAQ">GOEV</a>) is likely to report quarterly loss at $1.77 per share on revenue of $700 thousand.
&bull; GSE Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GVP#NASDAQ">GVP</a>) is likely to report quarterly loss at $0.81 per share on revenue of $12.07 million.
&bull; Acorda Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOR#NASDAQ">ACOR</a>) is likely to report earnings for its fourth quarter.
&bull; Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) is projected to report earnings for its fourth quarter.
&bull; SHF Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHFS#NASDAQ">SHFS</a>) is likely to report earnings for its fourth quarter.
&bull; Ideanomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDEX#NASDAQ">IDEX</a>) is likely to report earnings for its fourth quarter.
&bull; American Strategic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NYC#NYSE">NYC</a>) is estimated to report quarterly loss at $0.07 per share on revenue of $16.53 million.
&bull; Zomedica (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ZOM#AMEX">ZOM</a>) is expected to report earnings for its fourth quarter.
&bull; Microvast Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) is estimated to report quarterly loss at $0.07 per share on revenue of $94.43 million.
&bull; Paymentus Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAY#NYSE">PAY</a>) is projected to report quarterly earnings at $0.11 per share on revenue of $50.27 million.
&bull; IZEA Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IZEA#NASDAQ">IZEA</a>) is projected to report quarterly loss at $0.07 per share on revenue of $10.00 million.
&bull; Duos Technologies Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOT#NASDAQ">DUOT</a>) is expected to report quarterly loss at $0.25 per share on revenue of $3.00 million.
&bull; Pioneer Power Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPSI#NASDAQ">PPSI</a>) is expected to report quarterly earnings at $0.01 per share on revenue of $10.89 million.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

ACOR

AIRI

BKYI

DPSI

DUOT

EAST

EDBL

ENSV

ESCA

FPAY

GOEV

IDEX

IZEA

JAGX

LASE

LGMK

LLAP

LMFA

MLSS

MSGM

MVST

NNOX

NXGL

OMQS

ONDS

PPSI

PTIX

SACH

SGML

SGRP

SHF Holdings, Inc. - Class A Common Stock

SHFS

SKYX

SNAX

STSS

TLSI

TOMZ

VERO

VISL

VTSI

YTEN

Earnings Scheduled For April 1, 2024

The CNN Money Fear and Greed index showed a slight decline in overall market sentiment, but it remained in the &quot;Greed&quot; zone on Thursday.
U.S. stocks closed mixed on Thursday, while the S&amp;P 500 surged to a new all-time high and also recorded its best first-quarter performance in five years.
For the quarter, the S&amp;P 500 gained 10.2% to record its best first-quarter gain since 2019. The Dow Jones added 5.6% during the quarter, notching its best first-quarter performance since 2021. On the month, the S&amp;P 500 gained 3.1%, while the Dow added 2.1%.
Shares of MSC Industrial Direct Co., Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/msm#NYSE">MSM</a>) fell around 2.5% during Thursday&rsquo;s session after the company reported mixed second-quarter results. Walgreens Boots Alliance Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wba#NASDAQ">WBA</a>) reported better than expected second-quarter earnings and tightened FY24 guidance.
On the economic data front, the U.S. economy grew an annualized 3.4% in the fourth quarter, up from 3.2% previously reported. U.S. initial jobless claims fell by 2,000 to 210,000 in the week ending March 23, compared to market estimates of 215,000. The University of Michigan consumer sentiment rose to 79.4 in March versus a preliminary reading of 76.5.
Most sectors on the S&amp;P 500 closed on a positive note, with utilities, real estate and energy stocks recording the biggest gains on Wednesday. However, communication services and consumer discretionary bucked the overall market trend, closing the session lower.
The Dow Jones closed higher by around 47 points to 39,807.37 on Thursday. The S&amp;P 500 rose 0.11% at 5,254.35, while the Nasdaq Composite fell 0.12% at 16,379.46 during Thursday&rsquo;s session.
Investors are awaiting earnings results from Natural Gas Services Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ngs#NYSE">NGS</a>), Omeros Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/omer#NASDAQ">OMER</a>) and PVH Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pvh#NYSE">PVH</a>) today.
At a current reading of 70.6, the index remained in the &quot;Greed&quot; zone on Thursday, versus a prior reading of 70.8.
What is CNN Business Fear &amp; Greed Index?
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
&nbsp;
Read Next: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/03/37975916/jim-cramer-likes-crown-castle-but-cant-recommend-archer-aviation-it-has-no-earnings-powe"> Jim Cramer Likes Crown Castle, But Can&#39;t Recommend Archer Aviation: It Has &#39;No Earnings Power&#39;</a>
&nbsp;

Penny Stocks

Pre-Market Outlook

Investor Sentiment Edges Lower, US Stocks Record Gains Last Quarter

<h3>Gainers</h3>
<ul>
<li>Stoke Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>) shares increased by 77.7% to $11.55 during Monday's after-market session. The company's market cap stands at $515.7 million. As per the news, the Q4 earnings report came out today. </li>
<li>OpGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPGN#NASDAQ">OPGN</a>) shares moved upwards by 66.61% to $0.79. The market value of their outstanding shares is at $7.9 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock rose 11.62% to $1.92. The company's market cap stands at $7.0 million. </li>
<li>Vaxxinity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VAXX#NASDAQ">VAXX</a>) shares moved upwards by 7.99% to $0.72. The company's market cap stands at $90.8 million. </li>
<li>Unity Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBX#NASDAQ">UBX</a>) stock rose 7.39% to $1.7. The market value of their outstanding shares is at $28.4 million. </li>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) stock increased by 6.87% to $0.7. The market value of their outstanding shares is at $34.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Agile Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGRX#NASDAQ">AGRX</a>) shares declined by 54.7% to $0.27 during Monday's after-market session. </li>
<li>NeuBase Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBSE#NASDAQ">NBSE</a>) stock decreased by 54.53% to $0.45. The market value of their outstanding shares is at $1.6 million. </li>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) stock declined by 6.73% to $0.48. The market value of their outstanding shares is at $9.4 million. </li>
<li>Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) shares decreased by 6.69% to $3.21. The company's market cap stands at $201.7 million. </li>
<li>BIMI Intl Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIMI#NASDAQ">BIMI</a>) shares decreased by 6.46% to $1.73. The company's market cap stands at $24.2 million. </li>
<li>Regenxbio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>) stock decreased by 5.15% to $20.48. The company's market cap stands at $1.0 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AGRX

BCLI

BIMI

NBSE

OPGN

PRTG

RGNX

STOK

VAXX

12 Health Care Stocks Moving In Monday's After-Market Session

U.S. stocks were lower, with the Dow Jones index falling around 80 points on Monday.
Shares of Tesla, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>) fell during Monday&rsquo;s session after the company reportedly saw a <a href="https://www.benzinga.com/markets/asia/24/03/37451229/why-tesla-shares-are-down-over-1-premarket-today">decline in February China sales.</a>
Tesla sold 60,365 electric vehicles made in China in February, according to preliminary data released by the China Passenger Car Association, as reported by CnEVPost. The breakdown between exports and domestic sales will be available when the detailed report is released in a week.
Tesla shares fell 5.4% to $191.79 on Monday.
Here are some other big stocks recording losses&nbsp;in today&rsquo;s session.
<ul>
<li>MMTec, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mtc#NASDAQ">MTC</a>) shares fell 21.8% to $2.00.</li>
<li>Avidity Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rna#NASDAQ">RNA</a>) declined 16.6% to $16.78. Avidity Biosciences announced new long-term AOC 1001 data from the Marina-OLE trial showing reversal of disease progression in Myotonic Dystrophy Type 1 patients across multiple endpoints.</li>
<li>Playtika Holding Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pltk#NASDAQ">PLTK</a>) tumbled 14.8% to $6.44</li>
<li>New York Community Bancorp, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nycb#NASDAQ">NYCB</a>) declined 13.6% to $3.0650 after the company announced that it identified material weaknesses in its internal controls related to internal loan review, that resulted from ineffective oversight, risk assessment and monitoring activities.</li>
<li>Spirit Airlines, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/save#NYSE">SAVE</a>) dipped 12.1% to $5.68 after the company announced the termination of its merger agreement with JetBlue.</li>
<li>Lyell Immunopharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lyel#NASDAQ">LYEL</a>) fell 12.1% to $2.70.</li>
<li>Sabre Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sabr#NASDAQ">SABR</a>) declined 11.6% to $2.3050. Sabre announced exchange of $150 million of existing 4.000% exchangeable senior notes due 2025 for exchangeable senior notes due 2026.</li>
<li>Li Auto Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/li#NASDAQ">LI</a>) tumbled 11.6% to $38.49. B of A Securities analyst Ming Hsun Lee maintained Li Auto with a Buy and raised the price target from $57 to $60.</li>
<li>Revance Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rvnc#NASDAQ">RVNC</a>) dipped 11.2% to $6.20. Revance announced pricing of $100 million public offering of 16 million shares of common stock at a price of $6.25 per share.</li>
<li>Beyond Meat, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bynd#NASDAQ">BYND</a>) shares fell 11.3% to $8.67 after the company announced that it was unable to file its annual report due to technical difficulties in assembling the submission for filing. Also, the company said it anticipates it will seek to raise additional capital in 2024.</li>
<li>Cytek Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ctkb#NASDAQ">CTKB</a>) fell 11.1% to $8.14. Cytek Biosciences filed for non-timely 10-K with the U.S. SEC.</li>
<li>Sana Biotechnology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sana#NASDAQ">SANA</a>) fell 10.8% to $10.04. Sana Biotechnology recently reported a year-over-year increase in quarterly financial results.</li>
<li>ADS-TEC Energy PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adse#NASDAQ">ADSE</a>) fell 10.5% to $9.71.</li>
<li>ACM Research, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acmr#NASDAQ">ACMR</a>) declined 10.6% to $30.32.</li>
<li>EyePoint Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eypt#NASDAQ">EYPT</a>) fell 9.5% to $25.33. EyePoint Pharmaceuticals announced appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer.</li>
<li>Omeros Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/omer#NASDAQ">OMER</a>) fell 9.3% to $4.3350.</li>
<li>iRhythm Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/irtc#NASDAQ">IRTC</a>) tumbled 9% to $109.64. iRhythm announced a proposed offering of $450 million of convertible senior notes.</li>
<li>Hertz Global Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/htz#NYSE">HTZ</a>) dipped 7.2% to $7.26.</li>
<li>NIO Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nio#NYSE">NIO</a>) declined 6.9% to $5.38.</li>
<li>Rivian Automotive, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rivn#NASDAQ">RIVN</a>) fell 6.8% to $10.58.</li>
<li>Victoria&#39;s Secret &amp; Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vsco#NYSE">VSCO</a>) fell 5.8% to $26.77.</li>
<li>Unity Software Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/u#NYSE">U</a>) fell 5.3% to $27.36.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/24/03/37458044/bitcoin-surpasses-65-000-pepe-emerges-as-top-gainer"> Bitcoin Surpasses $65,000; Pepe Emerges As Top Gainer</a>

Small Cap

ACMR

ADSE

BYND

CTKB

EYPT

IRTC

LYEL

NYCB

PLTK

RIVN

RVNC

SABR

SANA

SAVE

TSLA

VSCO

Tesla, Spirit Airlines, New York Community Bancorp And Other Big Stocks Moving Lower On Monday

Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) today announced the upcoming presentation of a report detailing narsoplimab treatment in nine adult patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Narsoplimab is Omeros' investigational antibody targeting MASP-2, the effector enzyme of the lectin pathway of the complement system.
The report was authored by an external group of U.S. investigators involved in the treatment of these patients with narsoplimab provided under Omeros' compassionate use program. It will be featured as a poster presentation at the 2024 Tandem Meetings – the Transplantation &amp; Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy and the Center for International Blood and Marrow Transplant Research, to be held February 21-24, 2024 in San Antonio, Texas.
The poster will be presented by Lindsay Adkins, MSN, FNP-BC, BMTCN, of the Sarah Cannon Transplant and Cellular Therapy Program, Nashville, Tennessee. Details of the presentation are as follows:
Real-World Experience with Narsoplimab (OMS721) for the Treatment of Transplant-Associated Thrombotic Microangiopathy (Poster #186) Poster Session: Acute Regimen-Related Toxicity and Supportive Care Date: Thursday, February 22, 2024 Presentation Time: 6:45 - 7:45 p.m. CST Location: Exhibit Hall 4A
The presentation abstract is available now on the Tandem Meetings website at the following link:
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ftandem.confex.com%2Ftandem%2F2024%2Fmeetingapp.cgi%2FPaper%2F23952&amp;esheet=53898359&amp;newsitemid=20240220281063&amp;lan=en-US&amp;anchor=https%3A%2F%2Ftandem.confex.com%2Ftandem%2F2024%2Fmeetingapp.cgi%2FPaper%2F23952&amp;index=1&amp;md5=c16895f4a25187b342463d34b078be21">https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/23952</a>
The poster is expected to be made available on Omeros' website at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.investor.omeros.com&amp;esheet=53898359&amp;newsitemid=20240220281063&amp;lan=en-US&amp;anchor=www.investor.omeros.com&amp;index=2&amp;md5=009cd735b60ad14543e3d8e03099c1e1">www.investor.omeros.com</a> shortly after the meeting presentation.

Biotech

Events

General

Omeros Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use In Nine Patients With Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust Giving Omeros $115M Upfront Payment And Opportunity For Additional $55M In Sales-Based Milestones

As of Dec. 5, 2023, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#39;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#39;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi"> RSI is above 70</a>, according to <a href="https://pro.benzinga.com/"> Benzinga Pro</a>.
Here&rsquo;s the latest list of major overbought players in this sector.
<h3>EyePoint Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eypt#NASDAQ">EYPT</a>)</h3>
<ul>
<li>On Dec. 4, EyePoint Pharmaceuticals announced topline results of its Phase 2 DAVIO 2 trial of EYP-1901, an investigational sustained delivery maintenance treatment for wet age-related macular degeneration (wet AMD) combining vorolanib, a selective tyrosine kinase inhibitor with bioerodible Durasert E. The company&rsquo;s stock jumped around 198% over the past five days and has a <a href="https://www.benzinga.com/quote/EYPT">52-week high of $22.44 </a>.</li>
<li>RSI Value: 93.44</li>
<li>EYPT Price Action: Shares of EyePoint Pharmaceuticals jumped 177.5% to close at $18.34 on Monday.</li>
</ul>
<h3>Altimmune, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alt#NASDAQ">ALT</a>)</h3>
<ul>
<li>On Nov. 30, Altimmune announced topline results from its 48-week MOMENTUM Phase 2 obesity trial of pemvidutide with 391 subjects. The company&rsquo;s stock gained around 73% over the past month and <a href="https://www.benzinga.com/quote/ALT"> has a 52-week high </a> of $17.17.</li>
<li>RSI Value: 91.16</li>
<li>ALT Price Action: Shares of Altimmune gained 29.7% to close at $4.63 on Monday.</li>
</ul>
<h3>Omeros Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/omer#NASDAQ">OMER</a>)</h3>
<ul>
<li>On Nov. 9, Omeros posted a wider loss for the third quarter. &quot;Having discontinued our Phase 3 ARTEMIS-IGAN trial, we are closely examining the data to learn what happened and why so that we can apply the findings to the design and conduct of future renal clinical studies across our complement franchise,&quot; said Gregory A. Demopulos, M.D., Omeros&rsquo; chairman and chief executive officer. The company&rsquo;s stock jumped around 87% over the past month and has a <a href="https://www.benzinga.com/quote/OMER"> 52-week high </a> of $7.80.</li>
<li>RSI Value: 83.06</li>
<li>OMER Price Action: Shares of Omeros gained 13.9% to close at $2.54 on Monday.</li>
</ul>
<h3>Terns Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tern#NASDAQ">TERN</a>)</h3>
<ul>
<li>On Nov. 14, Terns Pharma posted a narrower quarterly loss. &ldquo;Throughout the third quarter and in recent weeks, we made meaningful progress across all three of our clinical development programs, opening U.S. Investigational New Drug (IND) applications, both for our allosteric BCR-ABL inhibitor TERN-701 for chronic myeloid leukemia (CML) and our lead small molecule oral GLP-1 agonist TERN-601 for obesity, and releasing Phase 2 data for our thyroid hormone receptor &beta; agonist TERN-501 from the DUET study in NASH patients,&rdquo; stated Erin Quirk, MD, president and head of research and development at Terns. The company&rsquo;s stock gained more than 56% over the past five days and has a 52-week high is $14.04.</li>
<li>RSI Value: 79.12</li>
<li>TERN Price Action: Shares of Terns Pharmaceuticals rose 16.3% to close at $6.07 on Monday.</li>
</ul>
<h3>Ocular Therapeutix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocul#NASDAQ">OCUL</a>)</h3>
<ul>
<li>On Nov. 7, Ocular Therapeutix posted a narrower-than-expected quarterly loss. &ldquo;We made significant progress at Ocular Therapeutix in the third quarter,&rdquo; said Antony Mattessich, President and CEO. The company&rsquo;s stock jumped 51% over the past five days and <a href="https://www.benzinga.com/quote/OCUL"> has a 52-week high </a> of $7.96.</li>
<li>RSI Value: 77.61</li>
<li>OCUL Price Action: Shares of Ocular Therapeutix gained 25.4% to close at $3.36 on Monday.</li>
</ul>
&nbsp;
Read More: <a href="https://www.benzinga.com/news/earnings/23/12/36085034/investor-sentiment-improves-further-fear-greed-index-remains-in-greed-zone"> Investor Sentiment Improves Further; Fear &amp; Greed Index Remains In &#39;Greed&#39; Zone </a>

Short Ideas

OCUL

TERN

Top 5 Health Care Stocks That Are Ticking Portfolio Bombs

The Dow Jones closed higher by over 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#39;s insider transactions </a> platform.
<h3>Omeros </h3>
<ul>
<li>The Trade: Omeros Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/omer#NASDAQ">OMER</a>) Director MD Peter Demopulos <a href="https://www.benzinga.com/quote/IVFH/analyst-ratings"> acquired a total of 10,000 shares </a> an average price of $1.53. To acquire these shares, it cost around $15,300.</li>
<li>What&rsquo;s Happening: Omeros posted a wider loss for the third quarter.</li>
<li>What Omeros Does: Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders.</li>
</ul>
<h3>Taysha Gene Therapies</h3>
<ul>
<li>The Trade: Taysha Gene Therapies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsha#NASDAQ">TSHA</a>) 10% owner Paul Manning <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 100,000 shares </a> at an average price of $1.63. To acquire these shares, it cost around $163,000.</li>
<li>What&rsquo;s Happening: Taysha Gene Therapies posted a wider third-quarter loss.</li>
<li>What Taysha Gene Therapies Does: Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/earnings/23/11/35887407/nvidia-best-buy-and-3-stocks-to-watch-heading-into-tuesday"> NVIDIA, Best Buy And 3 Stocks To Watch Heading Into Tuesday </a>
<h3>Gannett </h3>
<ul>
<li>The Trade: Gannett Co., Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gci#NYSE">GCI</a>) Director Laurence Tarica <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 200,000 shares </a> at an average price of $1.85. The insider spent around $370,000 to buy those shares.</li>
<li>What&rsquo;s Happening: Gannett and USA TODAY disclosed a multi-year strategic partnership with Home Solutions.</li>
<li>What Gannett Does: Gannett Co Inc is a digital newspaper company providing local media and marketing solutions in the U.S.</li>
</ul>
<h3>Atai Life Sciences </h3>
<ul>
<li>The Trade: Atai Life Sciences N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atai#NASDAQ">ATAI</a>) Florian Brand <a href="https://www.benzinga.com/quote/COMM/analyst-ratings"> acquired a total of 20,000 shares </a> at an average price of $1.16. The insider spent around $23,120 to buy those shares.</li>
<li>What&rsquo;s Happening: The company said net income attributable to shareholders for the three months ended Sept. 30, 2023 was $44.2 million.</li>
<li>What Atai Life Sciences Does: ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders.</li>
</ul>
&nbsp;
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>

Long Ideas

Insider Trades

ATAI

TSHA

Insiders Buying Taysha Gene Therapies And 3 Other Stocks Under $2

MD Gregory Demopulos, Chairman at Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>), reported a large insider buy on November 16, according to a new SEC filing. 
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001285819/000143774923032239//Archives/edgar/data/1285819/000143774923032239/0001437749-23-032239-index.htm">U.S. Securities and Exchange Commission</a> on Thursday showed that Demopulos purchased 62,500 shares of Omeros. The total transaction amounted to $84,375. 
Omeros shares are trading up 2.65% at $1.55 at the time of this writing on Thursday morning.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Important Transaction Codes</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001285819">Check Out The Full List Of Omeros's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Omeros Insider Trades Send a Signal

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Johnson & Johnson (JNJ – Research Report), Cullinan Management (C...

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Cullinan Management (CGEM) and Omeros (OMER)

GoodRx Holdings, Seelos Therapeutics, Clever Leaves among healthcare movers

Omeros plunges 20% following Q1 report, drug update

SYTA, DATS and CYN among mid-day movers

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sensei Biotherapeutics (SNSE – Research Report) an...

Analysts Offer Insights on Healthcare Companies: Sensei Biotherapeutics (SNSE) and Omeros (OMER)

Omeros: Troubled Company Working Its Way Out Of The Morass

Omeros Q2 2024 Earnings Preview

Omeros GAAP EPS of -$0.97 misses by $0.02

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Omeros (NASDAQ:<a href="https://investorplace.com/stock-quotes/omer-stock-quote/">OMER</a>) just reported results for the second quarter of 2024.<ul><li>Omeros reported earnings per share of -97 cents. This was below the analyst estimate for EPS of -69 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/omer-stock-earnings-omeros-for-q2-of-2024/">OMER Stock Earnings: Omeros Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Omeros

Omeros (OMER) Forecast

Omeros (NASDAQ:OMER) Stock, Quote.Headers.trade-ideas